Experimental study on transarterial administration of GRGDSP combined with transarterial chemoembolization in rats with hepatic carcinoma.
Cardiovasc Intervent Radiol 2007;
31:377-82. [PMID:
18058171 DOI:
10.1007/s00270-007-9233-0]
[Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/23/2006] [Revised: 01/30/2007] [Accepted: 10/16/2007] [Indexed: 12/19/2022]
Abstract
PURPOSE
To evaluate the effects of transarterial administration of an integrin antagonist, GRGDSP (Gly-Arg-Gly-Asp-Ser-Pro), combined with transarterial chemoembolization (TACE) to treat hepatic carcinoma in rats.
METHODS
Walker-256 tumor was implanted beneath the liver capsule in 26 Wistar rats. Animal subjects were assigned to groups based on which treatment was injected into the hepatic artery: group A, GRGDSP + TACE; group B, TACE alone; and group C, normal saline. Magnetic resonance imaging (MRI), tumor pathology, and immunohistochemistry were performed to assess each treatment.
RESULTS
The ratios of the post-treatment to pretreatment tumor volumes (V2/V1) in groups A, B, and C were 4.42 +/- 0.48, 6.98 +/- 1.09, and 13.00 +/- 1.68, respectively. The metastatic potential of the tumors was assessed by tumor cell nest counts, which were 5.00 +/- 1.25, 6.63 +/- 1.60, and 7.22 +/- 1.92 in groups A, B, and C, respectively. Microvessel density (MVD) was quantified by measuring von Willebrand factor density values, which were 0.18 +/- 0.02, 0.22 +/- 0.02, and 0.23 +/- 0.02 in groups A, B, and C, respectively.
CONCLUSIONS
Transarterial infusion of GRGDSP combined with TACE noticeably inhibited the growth of hepatic carcinoma and intrahepatic metastases in rats.
Collapse